Literature DB >> 10451443

Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality.

J M Legler1, L A Ries, M A Smith, J L Warren, E F Heineman, R S Kaplan, M S Linet.   

Abstract

BACKGROUND: During the 1980s, the incidence of primary malignant brain and other central nervous system tumors (hereafter called brain cancer) was reported to be increasing among all age groups in the United States, while mortality was declining for persons younger than 65 years. We analyzed these data to provide updates on incidence and mortality trends for brain cancer in the United States and to examine these patterns in search of their causes.
METHODS: Data on incidence, overall and according to histology and anatomic site, and on relative survival were obtained from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute for 1975 through 1995. Mortality data were obtained from the National Center for Health Statistics. Medicare procedure claims from the National Cancer Institute's SEER-Medicare database were used for imaging trends. Statistically significant changes in incidence trends were identified, and annual percent changes were computed for log linear models. RESULTS/
CONCLUSIONS: Rates stabilized for all age groups during the most recent period for which SEER data were available, except for the group containing individuals 85 years of age or older. Mortality trends continued to decline for the younger age groups, and the steep increases in mortality seen in the past for the elderly slowed substantially. Patterns differed by age group according to the site and grade of tumors between younger and older patients. During the last decade, use of computed tomography scans was relatively stable for those 65-74 years old but increased among those 85 years old or older. IMPLICATIONS: Improvements in diagnosis and changes in the diagnosis and treatment of elderly patients provide likely explanations for the observed patterns in brain cancer trends.

Entities:  

Mesh:

Year:  1999        PMID: 10451443     DOI: 10.1093/jnci/91.16.1382

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  114 in total

1.  mRNA stability alterations mediated by HuR are necessary to sustain the fast growth of glioma cells.

Authors:  Federico Bolognani; Anne-Isabelle Gallani; Lena Sokol; David S Baskin; Nicole Meisner-Kober
Journal:  J Neurooncol       Date:  2011-09-21       Impact factor: 4.130

Review 2.  Therapeutic window, a critical developmental stage for stem cell therapies.

Authors:  Shengwen Calvin Li; Yuan-Ping Han; Brent A Dethlefs; William G Loudon
Journal:  Curr Stem Cell Res Ther       Date:  2010-12       Impact factor: 3.828

3.  Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme.

Authors:  Inas S Khayal; Mei-Yin C Polley; Llewellyn Jalbert; Adam Elkhaled; Susan M Chang; Soonmee Cha; Nicholas A Butowski; Sarah J Nelson
Journal:  Neuro Oncol       Date:  2010-05-25       Impact factor: 12.300

4.  Thymidine kinase gene delivery using curcumin loaded peptide micelles as a combination therapy for glioblastoma.

Authors:  Jin Hyeong Park; Jaesik Han; Minhyung Lee
Journal:  Pharm Res       Date:  2014-08-27       Impact factor: 4.200

5.  PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.

Authors:  Hongbo Chen; Lin Mei; Lanzhen Zhou; Xiaomeng Shen; Caiping Guo; Yi Zheng; Huijun Zhu; Yongqiang Zhu; Laiqiang Huang
Journal:  J Neurooncol       Date:  2010-12-29       Impact factor: 4.130

6.  Racial/ethnic differences in survival among elderly patients with a primary glioblastoma.

Authors:  Jill S Barnholtz-Sloan; John L Maldonado; Vonetta L Williams; William T Curry; Elizabeth A Rodkey; Frederick G Barker; Andrew E Sloan
Journal:  J Neurooncol       Date:  2007-05-26       Impact factor: 4.130

7.  Measuring the optical characteristics of medulloblastoma with optical coherence tomography.

Authors:  Barry Vuong; Patryk Skowron; Tim-Rasmus Kiehl; Matthew Kyan; Livia Garzia; Cuiru Sun; Michael D Taylor; Victor X D Yang
Journal:  Biomed Opt Express       Date:  2015-03-25       Impact factor: 3.732

Review 8.  Tumor initiating cells in malignant gliomas: biology and implications for therapy.

Authors:  Costas G Hadjipanayis; Erwin G Van Meir
Journal:  J Mol Med (Berl)       Date:  2009-02-03       Impact factor: 4.599

9.  High Erk-1 activation and Gadd45a expression as prognostic markers in high risk pediatric haemolymphoproliferative diseases.

Authors:  Velia D'Angelo; Stefania Crisci; Fiorina Casale; Raffaele Addeo; Maria Giuliano; Elvira Pota; Paola Finsinger; Alfonso Baldi; Roberto Rondelli; Alberto Abbruzzese; Michele Caraglia; Paolo Indolfi
Journal:  J Exp Clin Cancer Res       Date:  2009-03-19

10.  Exploratory Visual Analysis of statistical results from microarray experiments comparing high and low grade glioma.

Authors:  David M Reif; Mark A Israel; Jason H Moore
Journal:  Cancer Inform       Date:  2007-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.